Jun 2026 (Q2 FY26) — Aug 12, 2026
OptimizeRx Q2 FY26 — Strong Profitability Amidst Revenue Headwinds and Strategic Innovation
Read the full callOptimizeRx (OPRX) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
OptimizeRx earnings: last reported Wed, 12 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 20.5 | −29.8% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -0.4 | −11.4 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -0.70 | −145.9% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Price
$8.74 +2.82% · +$0.24
Performance −55.3% 1Y
1Y: $19.55 on 17 Oct 2025 → $8.74. High $21.68 (24 Oct 2025), low $4.54 (23 Jun 2026).
- Previous close
- $8.5
- 52-week range
- $4.54 – $21.68
- One year
- −56.95%
Overview
- Symbol
- OPRX
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
OptimizeRx earnings calls (OPRX)
Financials
What the filings say
Net profit, year on year: −146% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 21 | 32 | 22 | 29 | 26 | 32 | 20 | 21 |
| Expenses | — | — | 24 | 26 | — | — | 19 | 21 |
| Operating profit | -9 | 4 | -2 | 3 | 2 | 9 | 0 | -0 |
| Operating margin | −40.2% | 11.3% | −9.6% | 11.0% | 7.9% | 26.6% | 2.0% | −0.4% |
| Other income | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 |
| Interest | 2 | 2 | 1 | 2 | 1 | 1 | 1 | 1 |
| Profit before tax | -10 | 2 | -3 | 2 | 1 | 7 | -1 | -1 |
| Tax rate | 8.2% | 103.6% | 32.8% | 11.5% | 25.7% | 32.8% | 23.1% | 35.9% |
| Net profit | -9 | -0 | -2 | 2 | 1 | 5 | -0 | -1 |
| EPS ($ per share) | -0.50 | — | -0.12 | 0.08 | 0.04 | — | -0.03 | -0.04 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -30 | -33 | -36 | -35 | -47 | -64 | -84 | -79 |
| Total liabilities | 7 | 12 | 10 | 10 | 9 | 57 | 54 | 49 |
| Fixed assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | — | — | — | — | 56 | — | 0 | 0 |
| Total assets | 25 | 57 | 60 | 141 | 135 | 183 | 171 | 177 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 1 | -2 | -6 | 1 | 11 | -7 | 5 | 19 |
| Cash from investing | -6 | -11 | -0 | -0 | -58 | -25 | -0 | 0 |
| Cash from financing | 9 | 22 | -2 | 74 | -19 | 28 | -5 | -9 |
| Net cash flow | — | 10 | -8 | 74 | -66 | -4 | -0 | 10 |
| Capital expenditure | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| Free cash flow | 1 | -2 | -6 | 1 | 11 | -7 | 5 | 19 |
Insider filings
41 filings between Nov 1, 2025 and Oct 1, 2026.
Open market
decisions to buy or sellNobody bought or sold OPRX on the open market in this window. The filings below are 11 awards, 5 option exercises and 25 tax withholdings.
Compensation
not trading decisions- 11
- Award — granted as compensation
- 5
- Option exercise — converted options into shares
- 25
- Tax withheld — shares kept back by the company to cover tax
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 1, 2026 | D'Silva Andrew J. Chief Business Officer | Tax withheld | 414 | $3.5K |
| Sep 1, 2026 | D'Silva Andrew J. Chief Business Officer | Tax withheld | 1,432 | $11.3K |
| Aug 21, 2026 | Silvestro Stephen L Chief Executive Officer | Tax withheld | 1,737 | $13.4K |
| Aug 21, 2026 | Odence-Ford Marion Chief Legal & Admin Officer | Tax withheld | 1,529 | $11.8K |
| Aug 21, 2026 | D'Silva Andrew J. Chief Business Officer | Tax withheld | 1,243 | $9.6K |
| Aug 21, 2026 | Stelmakh Edward Chief Finance & Strat Officer | Tax withheld | 1,381 | $10.6K |
| Aug 21, 2026 | Merrell Brendan W. CHIEF OPERATING OFFICER | Tax withheld | 1,020 | $7.9K |
| Aug 20, 2026 | Merrell Brendan W. CHIEF OPERATING OFFICER | Award | 57,600 | $0 |
| Aug 20, 2026 | D'Silva Andrew J. Chief Business Officer | Award | 57,600 | $0 |
| Aug 20, 2026 | Silvestro Stephen L Chief Executive Officer | Award | 79,200 | $0 |
| Aug 20, 2026 | Odence-Ford Marion Chief Legal & Admin Officer | Award | 57,600 | $0 |
| Jun 9, 2026 | Presti Mariyamma Varghese Director | Award | 17,258 | $0 |
| Jun 9, 2026 | Spangler Patrick D Director | Award | 34,517 | $0 |
| Jun 9, 2026 | Lang James Paul Director | Award | 34,517 | $0 |
| Jun 9, 2026 | Vos Ellen O'Connor Director | Award | 34,517 | $0 |
| Jun 9, 2026 | WASSON GREGORY D Director | Award | 34,517 | $0 |
| Jun 9, 2026 | KLEMA CATHY Director | Award | 34,517 | $0 |
| May 15, 2026 | Silvestro Stephen L Chief Executive Officer | Tax withheld | 5,219 | $27.2K |
| May 15, 2026 | Greco Theresa Chief Commercial Officer | Tax withheld | 879 | $4.6K |
| May 15, 2026 | Greco Theresa Chief Commercial Officer | Tax withheld | 914 | $4.8K |
| May 1, 2026 | Presti Mariyamma Varghese Director | Award | 13,060 | $0 |
| Feb 11, 2026 | Odence-Ford Marion Chief Legal & Admin Officer | Tax withheld | 1,386 | $12.8K |
| Feb 11, 2026 | Odence-Ford Marion Chief Legal & Admin Officer | Option exercise | 4,000 | — |
| Dec 23, 2025 | Silvestro Stephen L Chief Executive Officer | Tax withheld | 3,361 | $42.8K |
| Dec 23, 2025 | Greco Theresa Chief Commercial Officer | Tax withheld | 1,420 | $18.1K |
| Dec 23, 2025 | Odence-Ford Marion Chief Legal & Admin Officer | Tax withheld | 4,051 | $51.6K |
| Dec 23, 2025 | Stelmakh Edward Chief Finance & Strat Officer | Tax withheld | 3,658 | $46.6K |
| Dec 23, 2025 | Besch Doug Chief Product & Tech Officer | Tax withheld | 4,079 | $52.0K |
| Dec 19, 2025 | Stelmakh Edward Chief Finance & Strat Officer | Tax withheld | 1,388 | $18.8K |
| Dec 19, 2025 | Stelmakh Edward Chief Finance & Strat Officer | Option exercise | 5,237 | $0 |
| Dec 19, 2025 | D'Silva Andrew J. Chief Business Officer | Tax withheld | 703 | $9.5K |
| Dec 19, 2025 | Besch Doug Chief Product & Tech Officer | Tax withheld | 581 | $7.8K |
| Dec 19, 2025 | Merrell Brendan W. CHIEF OPERATING OFFICER | Tax withheld | 289 | $3.9K |
| Dec 19, 2025 | Silvestro Stephen L Chief Executive Officer | Tax withheld | 1,594 | $21.5K |
| Dec 19, 2025 | Besch Doug Chief Product & Tech Officer | Option exercise | 1,964 | $0 |
| Dec 19, 2025 | Silvestro Stephen L Chief Executive Officer | Option exercise | 6,546 | $0 |
| Dec 19, 2025 | Odence-Ford Marion Chief Legal & Admin Officer | Tax withheld | 1,153 | $15.6K |
| Dec 19, 2025 | Odence-Ford Marion Chief Legal & Admin Officer | Option exercise | 3,928 | $0 |
| Dec 11, 2025 | D'Silva Andrew J. Chief Business Officer | Tax withheld | 868 | $12.2K |
| Dec 11, 2025 | Merrell Brendan W. CHIEF OPERATING OFFICER | Tax withheld | 712 | $10.0K |
| Nov 1, 2025 | Greco Theresa Chief Commercial Officer | Tax withheld | 1,693 | $34.7K |
| Oct 3, 2025 | Merrell Brendan W. CHIEF OPERATING OFFICER | Tax withheld | 483 | $9.1K |
| Oct 3, 2025 | D'Silva Andrew J. Chief Business Officer | Tax withheld | 794 | $14.9K |
| Oct 3, 2025 | Silvestro Stephen L Chief Executive Officer | Sale | 1,620 | $30.4K |
| Oct 3, 2025 | Silvestro Stephen L Chief Executive Officer | Option exercise | 6,649 | $0 |
| Oct 3, 2025 | Stelmakh Edward Chief Finance & Strat Officer | Tax withheld | 4,406 | $82.6K |
| Oct 3, 2025 | Stelmakh Edward Chief Finance & Strat Officer | Option exercise | 16,623 | $0 |
| Oct 3, 2025 | Besch Doug Chief Product & Tech Officer | Tax withheld | 983 | $18.4K |
| Oct 3, 2025 | Besch Doug Chief Product & Tech Officer | Option exercise | 3,325 | $0 |
| Oct 3, 2025 | Odence-Ford Marion Chief Legal & Admin Officer | Option exercise | 6,649 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for OptimizeRx Corp
Free account. Everything above stays public.
Write why you follow OptimizeRx Corp and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading